White House says U.S. will run out of money to fight pandemic if Congress doesn’t pass Covid funding bill

White House says U.S. will run out of money to fight pandemic if Congress doesn’t pass Covid funding bill


A healthcare worker prepares a dose of the Pfizer-BioNTech Covid-19 vaccine at a vaccination clinic in the Peabody Institute Library in Peabody, Massachusetts, on Wednesday, Jan. 26, 2022.

Vanessa Leroy | Bloomberg | Getty Images

The White House on Tuesday warned the U.S. won’t have enough booster shots and lifesaving Covid treatments for Americans if Congress fails to pass $22.5 billion in additional pandemic funding.

Senior Biden administration officials, on a call with reporters, said the U.S. could face another wave of Covid infections in the coming months, even as new cases and hospitalizations have dramatically declined from the peak of the unprecedented omicron surge in January. Infections are already on the rise again in major European nations, such as the U.K. and Germany. China is battling its worst outbreak since 2020.

The officials warned the funding is urgently needed to get ahead of another Covid wave. House Democrats last week stripped $15 billion in coronavirus funding, which was already less than Biden requested, from a broader spending bill after failing to reach a bipartisan agreement with Republicans. The GOP has insisted that Congress offset new Covid money by cutting funds for state and local governments allocated for the spring, a demand many Democrats were unwilling to accept.

The senior administration officials told reporters the federal government will not be able to purchase enough booster shots, vaccines that target specific variants or more antiviral pills beyond the 20 million already on order from Pfizer if more funding isn’t approved.

There is also no more funding for additional monoclonal antibody treatments, including an order planned for March 25, the officials said. If more funding doesn’t come through, the federal government will have to cut state allocations of monoclonal antibodies by more than 30% starting next week, they said.

CNBC Health & Science

Read CNBC’s latest global coverage of the Covid pandemic:

The federal government will also not be able to maintain sufficient Covid testing capacity beyond June in the event of another surge, the officials said. During the omicron wave, there was a run on at-home tests and in-person clinics, resulting in hourslong lines and empty pharmacy shelves.

Uninsured people will also no longer have coverage for Covid testing and treatments, according to the White House. The fund that covers them will stop accepting new claims a week from now, forcing health-care providers to either absorb the costs or turn patients away, the officials said. The fund will completely end in early April and the uninsured will no longer have coverage for vaccinations, they said.

Some investments made in surveillance of new Covid variants will also have to be wound down, the officials said, leaving the U.S. without the capabilities it needs to stay on top of how the virus is evolving. The emergence of the highly mutated omicron variant blindsided the U.S. and much of the world in November.

The White House said the money is also needed to fund the development of a vaccine that covers a range of Covid variants, and support the administration’s efforts to help increase the vaccination rate in developing nations. Without the money, the risk will rise that new variants will emerge, the officials said. Omicron emerged in South Africa and Botswana, and the delta variant was first identified in India.

 — CNBC’s Ylan Mui contributed to this report.



Source

Jim Cramer: Abbott stock is ‘dirt cheap’ after a surprising legal win validates our conviction
Health

Jim Cramer: Abbott stock is ‘dirt cheap’ after a surprising legal win validates our conviction

Abbott Laboratories shares jumped Friday after the Club holding picked up a surprise victory in a trial over the safety of its formula for premature babies. The news Abbott Labs’ specialized formula is not responsible for a young baby boy developing a severe intestinal illness known as necrotizing enterocolitis, or NEC, a jury in Missouri […]

Read More
Healthy Returns: Wegovy may reduce knee pain in patients with a type of arthritis and obesity
Health

Healthy Returns: Wegovy may reduce knee pain in patients with a type of arthritis and obesity

The “Wegovy” brand slimming syringe is sold in the Achat pharmacy in Mitte. The “Wegovy” slimming syringe has been available in Germany for a year. Jens Kalaene | Picture Alliance | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. […]

Read More
Palo Alto shares helped by contract news, Abbott Labs braces for lawsuit ruling
Health

Palo Alto shares helped by contract news, Abbott Labs braces for lawsuit ruling

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Markets: Wall Street is under pressure Thursday, led to the downside by the tech-heavy Nasdaq Composite , which dropped more than 2%. The S & P […]

Read More